Research and context
Boots is launching SureLeaf alongside a collaborative research programme with the University of Nottingham that will examine patient outcomes, prescribing practices and experience in the treatment of chronic pain. The prescription of cannabis-derived medicines was legalised in the UK in 2018. Only people with rare forms of epilepsy, those dealing with certain side-effects of chemotherapy, and those with certain multiple sclerosis symptoms can get it on the NHS. Private clinics have been treating patients with cannabis-derived medicines for years.
Jamie Kerruish, Boots’ chief healthcare officer, said: “Millions of people live with ongoing pain and, for some, conventional treatments do not provide adequate symptom relief. This can have a significant impact on everyday life, from working and sleeping well to spending time with family and doing the things they enjoy.”
Dr David Gwynne, the medical director of Boots’ online service, said: “Medical cannabis is not appropriate for everyone and prescribing decisions need to be made carefully on an individual patient basis.”